The France Contraceptive Devices Market size is estimated at USD 458.16 million in 2024, and is expected to reach USD 624.78 million by 2029, growing at a CAGR of 6.40% during the forecast period (2024-2029).
The pandemic adversely impacted the contraceptive devices market in France. For instance, as per the study published in April 2022, by the National Library of Medicine, the dispensing of contraceptives in France was remarkably low during the COVID-19 pandemic. Prescriptions for long-acting contraceptive use and women under 25 years were the most substantially impacted. Dispensing of emergency contraceptives (EC) and intrauterine contraceptives decreased more substantially during the first lockdown and then increased moderately at the end of 2020 and in 2021. Hence, with the resumption of services due to the decrease in COVID-19 cases, the market started to recover and is expected to maintain its growth over the forecast period.
The increasing awareness about sexually transmitted diseases (STDs), the rising rate of unintended pregnancies, and the rise in government initiatives are the major factors driving the market. For instance, in November 2021, a report published by the WHO stated that sexual intercourse is the second most commonly reported mode of transmission of STDs in the European Union, accounting for 29.7% of all HIV diagnoses. The highest proportions were observed in France (53.0%) in 2021. Thus, the high burden of STDs in France than other European countries is expected to increase the demand for contraceptive devices, which is expected to boost the market's growth over the forecast period.
Similarly, the report published in October 2021 by the HPV World stated that the prevalence of HPV 16 and 18 among adult women with normal cytology is 4.7%, with low-grade cervical lesions is 26.3%, with high-grade cervical lesions is 60.6%, and with cervical cancer is 75.6%. Such instances indicate that the demand for contraceptive devices may increase. Thereby, considerable market growth is anticipated over the forecast period.
However, side effects associated with the use of contraceptive devices may likely restrain the market over the forecast period.
A condom is a sheath-shaped barrier device used during sexual intercourse to reduce the probability of pregnancy or a sexually transmitted infection (STI). There are both male and female condoms. With proper use, women whose male partners use condoms experience a 2.0% per-year pregnancy rate. Their use greatly decreases the risk of gonorrhea, chlamydia, trichomoniasis, hepatitis B, and HIV/AIDS. To a lesser extent, they also protect against genital herpes, human papillomavirus (HPV), and syphilis.
The increasing demand for condoms and rising cases of sexually transmitted diseases in France are the major factors propelling the segment's growth. For instance, as per the report published by the World Population Review in February 2022, around 0.30% of the population of France had HIV in 2021. Similarly, as per the study published in May 2022 by PLOS, syphilis prevalence and incidence were relatively high in France in 2021, especially among males who have sex with males with controlled HIV infection and pre-exposure prophylaxis users. The study also recommended that syphilis screening should be increased and behavioral risk reduction counseling among high-risk subjects should be conducted. Condoms are one of the essential requirements to lower the cases of sexually transmitted diseases in France.
The female segment in the contraceptive devices market is expected to witness significant growth over the forecast period owing to the increased adoption of contraceptive devices, rising sexually transmitted diseases, and a growing number of unintended pregnancies.
Rising initiatives from European countries on contraception for their residents are expected to drive the growth of this market in France. For instance, in December 2021, to prevent young women from stopping their use of contraception because they cannot afford it, France will begin offering free birth control to all women under 25. The program, which potentially helps three million women, includes coverage for the pill, intrauterine devices (IUDs), contraceptive patches, and other steroid hormone-based techniques. Such initiatives from the government are likely to drive the market's growth over the forecast period.
Rising initiatives from European governments for safe sex in their countries, especially among teenagers, are expected to drive the growth of this segment in Europe. For instance, according to the news published in March 2021, 96% of France's schools have condom vending machines to encourage healthy sex and lower the chance of teen pregnancy. Such initiatives in the country are also supporting market growth.
The French contraceptive devices market is moderately competitive and fragmented in nature. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including AbbVie Inc. (Allergan), Bayer Healthcare, Cooper Surgical Inc., and Mylan Laboratories.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook